- Home
- GMAB vs BAP Comparison
GMAB vs BAP Comparison
Compare GMAB & BAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- BAP
- Stock Information
- Founded
- GMAB 1999
- BAP 1889
- Country
- GMAB Denmark
- BAP Peru
- Employees
- GMAB N/A
- BAP N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- BAP Major Banks
- Sector
- GMAB Health Care
- BAP Finance
- Exchange
- GMAB Nasdaq
- BAP Nasdaq
- Market Cap
- GMAB 17.4B
- BAP 21.1B
- IPO Year
- GMAB N/A
- BAP 1995
- Fundamental
- Price
- GMAB $28.66
- BAP $259.52
- Analyst Decision
- GMAB Strong Buy
- BAP Buy
- Analyst Count
- GMAB 7
- BAP 6
- Target Price
- GMAB $41.50
- BAP $245.00
- AVG Volume (30 Days)
- GMAB 2.6M
- BAP 255.6K
- Earning Date
- GMAB 11-06-2025
- BAP 11-13-2025
- Dividend Yield
- GMAB N/A
- BAP 4.24%
- EPS Growth
- GMAB 132.41
- BAP 26.90
- EPS
- GMAB 25.10
- BAP 22.19
- Revenue
- GMAB $3,845,670,022.00
- BAP $5,576,317,301.00
- Revenue This Year
- GMAB $24.92
- BAP $24.87
- Revenue Next Year
- GMAB $15.97
- BAP $7.51
- P/E Ratio
- GMAB $11.14
- BAP $11.70
- Revenue Growth
- GMAB 29.57
- BAP 20.05
- 52 Week Low
- GMAB $17.24
- BAP $165.51
- 52 Week High
- GMAB $33.65
- BAP $280.88
- Technical
- Relative Strength Index (RSI)
- GMAB 40.06
- BAP 49.55
- Support Level
- GMAB $28.08
- BAP $254.10
- Resistance Level
- GMAB $29.35
- BAP $263.01
- Average True Range (ATR)
- GMAB 0.65
- BAP 4.67
- MACD
- GMAB -0.27
- BAP 0.25
- Stochastic Oscillator
- GMAB 25.93
- BAP 57.35
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About BAP Credicorp Ltd.
Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.